These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25827099)

  • 1. Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.
    Frederix GW; Haji Ali Afzali H; Dasbach EJ; Ward RL
    Pharmacoeconomics; 2015 Aug; 33(8):777-81. PubMed ID: 25827099
    [No Abstract]   [Full Text] [Related]  

  • 2. Approaches for economic evaluations of health care technologies.
    Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
    Barbieri M; Hawkins N; Sculpher M
    Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model Structuring for Economic Evaluations of New Health Technologies.
    Haji Ali Afzali H; Bojke L; Karnon J
    Pharmacoeconomics; 2018 Nov; 36(11):1309-1319. PubMed ID: 30030816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic data transferability for HTA: are we there yet?
    Manca A
    Value Health; 2009 Jun; 12(4):407. PubMed ID: 19900247
    [No Abstract]   [Full Text] [Related]  

  • 6. [Discrete-event simulation models in the economic evaluation of health technologies and health products].
    Rodríguez Barrios JM; Serrano D; Monleón T; Caro J
    Gac Sanit; 2008; 22(2):151-61. PubMed ID: 18420015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages and disadvantages of discrete-event simulation for health economic analyses.
    Caro JJ; Möller J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):327-9. PubMed ID: 26967022
    [No Abstract]   [Full Text] [Related]  

  • 8. Presentation of economic evaluation results.
    Chaikledkaew U
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S72-80. PubMed ID: 24964702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An introduction to the methods of cost-effectiveness analysis.
    Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based decision-making 3: Health technology assessment.
    O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
    Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transparency of economic evaluations of health technologies.
    Rovira J
    Pharmacoeconomics; 2008; 26(3):181-3. PubMed ID: 18282013
    [No Abstract]   [Full Text] [Related]  

  • 12. IQWiG: an opportunity lost?
    Jönsson B
    Eur J Health Econ; 2008 Aug; 9(3):205-7. PubMed ID: 18496721
    [No Abstract]   [Full Text] [Related]  

  • 13. Quality assessment of health economic evaluation.
    Chaikledkaew U; Kittrongsiri K
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S113-8. PubMed ID: 24964708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health technologies for rare diseases: does conventional HTA still apply?
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):315-7. PubMed ID: 24702042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reimbursement programs and health technology assessment for diabetes devices and supplies: a Canadian perspective.
    Cheung RY; Mui V
    J Diabetes Sci Technol; 2015 May; 9(3):706-10. PubMed ID: 25697719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring structural uncertainty in model-based economic evaluations.
    Afzali HH; Karnon J
    Pharmacoeconomics; 2015 May; 33(5):435-43. PubMed ID: 25601288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Decision modeling for economic evaluation of health technologies].
    de Soárez PC; Soares MO; Novaes HM
    Cien Saude Colet; 2014 Oct; 19(10):4209-22. PubMed ID: 25272129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health technology assessment in Europe.
    Kristensen FB
    Scand J Public Health; 2009 Jun; 37(4):335-9. PubMed ID: 19493989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.